National Bank Of Canada Arcus Biosciences, Inc. Transaction History
National Bank Of Canada
- $57.5 Billion
- Q1 2024
A detailed history of National Bank Of Canada transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, National Bank Of Canada holds 100 shares of RCUS stock, worth $1,465. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$1,465
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
186Shares Held
49.2MCall Options Held
204KPut Options Held
149K-
Black Rock Inc. New York, NY9.9MShares$145 Million0.0% of portfolio
-
State Street Corp Boston, MA4.9MShares$71.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.79MShares$70.2 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.88MShares$42.2 Million0.52% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$28.1 Million0.09% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.06B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...